20651-30-3

Basic information

• Product Name: 4(3H)-Pyrimidinone, 5-methyl-2-(methylthio)-
• Synonyms: 4(3H)-Pyrimidinone, 5-methyl-2-(methylthio)-;2-(Methylthio)-5-methylpyrimidine-4(1H)-one;5-Methyl-2-methylthio-4(1H)-pyrimidinone;5-Methyl-2-(Methylthio)pyriMidin-4(3H)-one;5-methyl-2-(methylthio)pyrimidin-4(1H)-one;2-(methylthio)-5-methylpyrimidin-4(1H)-one
• CAS NO: 20651-30-3
• Molecular Formula: C₆H₈N₂OS
• Molecular Weight: 156.21
• Mol File: 20651-30-3.mol
• Article Data: 13

Chemical Properties

• Appearance: /
• Density: 1.3 g/cm³
• Refractive Index: 1.618
• Storage Temp.: 2-8°C(protect from light)
• CAS DataBase Reference: 4(3H)-Pyrimidinone, 5-methyl-2-(methylthio)-(CAS DataBase Reference)
• NIST Chemistry Reference: 4(3H)-Pyrimidinone, 5-methyl-2-(methylthio)-(20651-30-3)
• EPA Substance Registry System: 4(3H)-Pyrimidinone, 5-methyl-2-(methylthio)-(20651-30-3)

Safety Data

• Hazardous Substances Data: 20651-30-3(Hazardous Substances Data)

Usage

General Description

4(3H)-Pyrimidinone, 5-methyl-2-(methylthio)- is a chemical compound often abbreviated as TPM. Its systematic name is 5-methyl-2-(methylthio)pyrimidin-4(3H)-one, signalling its structural composition. 4(3H)-Pyrimidinone, 5-methyl-2-(methylthio)- has a molecular formula of C6H8N2OS and exhibits properties typically linked to heterocyclic compounds. Its applications are primarily in the field of organic chemistry and pharmaceutical research. It has a molecular weight of 156.21 g/mol and is generally synthesized by skilled chemists in controlled laboratory settings.

InChI:InChI=1/C6H8N2OS/c1-4-3-7-6(10-2)8-5(4)9/h3H,1-2H3,(H,7,8,9)

Upstream product

• 190070-16-7 4-(5-Methyl-2-methylsulfanyl-6-oxo-6H-pyrimidin-1-ylmethyl)-5-pyrrolidin-1-yl-4,5-dihydro-isoxazole-3-carboxylic acid ethyl ester 
• 27772-62-9 ethyl 2-formylpropionate 
• 74-88-4 methyl iodide 
• 65-71-4 thymin 
• 4401-71-2 1,3-dimethylthymine 
• 636-26-0 5-methyl-2-thiouracil 
• 51673-64-4 methyl 2-methyl-3-oxopropanoate 
• 4338-95-8 S-methylthiouronium iodide 
• 636-26-0 5-methyl-2-thiouracil 
• 1026541-14-9 5-Methyl-2-methylsulfanyl-3-((E)-3-pyrrolidin-1-yl-allyl)-3H-pyrimidin-4-one 
• 190070-08-7 3-(5-Methyl-2-methylsulfanyl-6-oxo-6H-pyrimidin-1-yl)-propionaldehyde 
• 14337-43-0 ethyl 2-chloro-2-(hydroxyimino)acetate 

Downstream Products

• 65-71-4 2,4-dihydroxy-5-methylpyrimidine 
• 61044-96-0 4-chloro-5-methyl-2-(methylsulfanyl)pyrimidine 
• 191871-18-8 4-[[(5-methyl-4(3H)-oxopyrimidin-2-yl)amino]methyl]benzonitrile 
• 1140520-11-1 C₁₂H₁₀N₄O 
• 191871-19-9 4-[[(5-methyl-4(3H)-oxopyrimidin-2-yl)amino]-methyl]benzenemethanamine 
• 1232683-93-0 C₁₉H₁₃BrN₄O 
• 1610953-81-5 C₂₃H₂₂N₄O 
• 1232185-54-4 C₂₀H₁₄BrN₅ 

Relevant articles and documents

Synthesis of 2-bromomethyl-3-hydroxy-2-hydroxymethyl-propyl pyrimidine and theophylline nucleosides under microwave irradiation. Evaluation of their activity against hepatitis B virus

Alkylation of 2-methylthiopyrimidin-4(1H)-one (1a) and its 5(6)-alkyl derivatives 1b - d as well as theophylline (7) with 2,2- bis (bromomethyl)-1,3-diacetoxypropane (2) under microwave irradia-tion gave the corresponding acyclonucleosides 1-[(3-acetoxy-2-acetoxymethyl-2-bromomethyl) prop-1- yl ]-2-methyl-thio pyrmidin-4(1H)-ones 3a - d and 7-[(3-acetoxy-2- acetoxymethyl-2-bromomethyl)prop-1- yl]theophylline (8), which upon further irradiation gave the double-headed acyclonucleosides 1,1 ′-[(2,2- diacetoxymethyl)-1,3-propylidene]- bis [(2-(methylthio)-pyrimidin-4(1H)-ones] 4a - c , and 7,7 ′-[(2,2-diacetoxymethyl)-1,3-propylidene]- bis (theophylline) (9). The deacetylated derivatives were obtained by the action of sodium methoxide. The activity of deacetylated nucleosides against Hepatitis B virus was evaluated. Compound 5b showed moderate inhibition activity against HBV with mild cytotoxicity. Copyright Taylor & Francis Group, LLC.

Synthesis and biological evaluation of DAPY-DPEs hybrids as non-nucleoside inhibitors of HIV-1 reverse transcriptase

A series of new DAPY-DPEs hybrids, combined the important pharmacophores of DAPYs and DPEs, has been synthesized and biologically evaluated for their anti-HIV activities against wild-type HIV-1 strain IIIB, double RT mutant (K103N + Y181C) strain RES056 and HIV-2 strain ROD in MT-4 cell cultures. Many promising candidates with potent inhibitory activity (wild-type) within the EC50 range from 0.16 to 0.013 μM were obtained. In particular, 3c, 3p, 3r and 3s displayed low nM level EC50 values (35, 13, 50 and 17 nM, respectively) and high selectivity (9342, 25131, 2890 and 11338, respectively), which were much more potent than NVP (EC50 = 0.31 μM, SI = 48), 3TC (EC50 = 2.24 μM, SI > 39), DDI (EC50 = 23.20 μM, SI > 9) and DLV (EC50 = 0.65 μM, SI > 67), and comparable to AZT (EC50 = 0.0071 μM, SI > 13144) and EFV (EC50 = 0.0062 μM, SI > 1014). The HIV-1 reverse transcriptase inhibitory assay confirmed that these DAPY-DPEs hybrids targeted HIV-1 RT. Molecular simulation was performed to investigate the potential binding mode of the newly synthesized compounds. And reasonable explanation for the activity results was discussed with docking method.

Synthesis and biological evaluation of CHX-DAPYs as HIV-1 non-nucleoside reverse transcriptase inhibitors

A series of new diarylpyrimidines (DAPYs) characterized by a halogen atom on the methylene linker between wing I and the central pyrimidine ring was synthesized and evaluated for their anti-HIV activity in MT-4 cell cultures. The two most promising compou